PI3K/Akt/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors

Cancer Letters

Volumn 335, Issue 1, 2013, Pages 1-8

  Wolin, Edward M ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Akt; Inhibitor; MTOR; Neuroendocrine tumors; Pancreatic; PI3K

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; BEVACIZUMAB; CC 223; CIXUTUMUMAB; ERLOTINIB; EVEROLIMUS; HEAT SHOCK PROTEIN 90; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; OCTREOTIDE; PASIREOTIDE; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; RAPAMYCIN; RIDAFOROLIMUS; SORAFENIB; TEMOZOLOMIDE; TEMSIROLIMUS; TRICIRIBINE; TUBERIN; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; CARCINOGENESIS; DRUG APPROVAL; DRUG EFFICACY; ENZYME ACTIVATION; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; GENE MUTATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; LEUKOPENIA; LYMPHOCYTOPENIA; NONHUMAN; PANCREAS ISLET CELL CARCINOMA; PANCREATIC NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; SHORT SURVEY; SOLID TUMOR;

EID: 84878437544     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.02.016     Document Type: Review

References (70)

1. Yao J.C., Hassan M., Phan A., Dagohoy C., Leary C., Mares J.E., Abdalla E.K., Fleming J.B., Vauthey J.N., Rashid A., Evans D.B. One hundred years after " carcinoid" : epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the united states. J. Clin. Oncol. 2008, 26:3063-3072.
2. Oberstein P.E., Remotti H., Saif M.W., Libutti S.K. Pancreatic neuroendocrine tumors: Entering a new era. J. Pancreas 2012, 13:169-173.
3. Yao J.C., Eisner M.P., Leary C., Dagohoy C., Phan A., Rashid A., Hassan M., Evans D.B. Population-based study of islet cell carcinoma. Ann. Surg. Oncol. 2007, 14:3492-3500.
4. Capdevila J., Tabernero J. A shining light in the darkness for the treatment of pancreatic neuroendocrine tumors. Cancer Discov. 2011, 1:213-221.
5. Metz D.C., Jensen R.T. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 2008, 135:1469-1492.
6. Agarwal S.K., Lee Burns A., Sukhodolets K.E., Kennedy P.A., Obungu V.H., Hickman A.B., Mullendore M.E., Whitten I., Skarulis M.C., Simonds W.F., Mateo C., Crabtree J.S., Scacheri P.C., Ji Y., Novotny E.A., Garrett-Beal L., Ward J.M., Libutti S.K., Richard Alexander H., Cerrato A., Parisi M.J., Santa Anna-A S., Oliver B., Chandrasekharappa S.C., Collins F.S., Spiegel A.M., Marx S.J. Molecular pathology of the MEN1 gene. Ann. NY. Acad. Sci. 2004, 1014:189-198.
7. Kulke M.H., Bendell J., Kvols L., Picus J., Pommier R., Yao J. Evolving diagnostic and treatment strategies for pancreatic neuroendocrine tumors. J. Hematol. Oncol. 2011, 4:29.
8. Jensen R.T., Berna M.J., Bingham D.B., Norton J.A. Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies. Cancer 2008, 113:1807-1843.
9. Jensen R.T., Delle Fave G. Promising advances in the treatment of malignant pancreatic endocrine tumors. N. Engl. J. Med. 2011, 364:564-565.
10. Moertel C.G., Lefkopoulo M., Lipsitz S., Hahn R.G., Klaassen D. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N. Engl. J. Med. 1992, 326:519-523.
11. Kouvaraki M.A., Ajani J.A., Hoff P., Wolff R., Evans D.B., Lozano R., Yao J.C. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J. Clin. Oncol. 2004, 22:4762-4771.
12. Kulke M.H., Hornick J.L., Frauenhoffer C., Hooshmand S., Ryan D.P., Enzinger P.C., Meyerhardt J.A., Clark J.W., Stuart K., Fuchs C.S., Redston M.S. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin. Cancer Res. 2009, 15:338-345.
13. Strosberg J.R., Fine R.L., Choi J., Nasir A., Coppola D., Chen D.T., Helm J., Kvols L. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011, 117:268-275.
14. Ekeblad S., Sundin A., Janson E.T., Welin S., Granberg D., Kindmark H., Dunder K., Kozlovacki G., Orlefors H., Sigurd M., Oberg K., Eriksson B., Skogseid B. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin. Cancer Res. 2007, 13:2986-2991.
15. S. Alsamarai, S.K. Libutti, M.W. Saif, Updates in pancreatic neuroendocrine carcinoma. highlights from the " 2010 ASCO annual meeting" , in: J. Pancreas, vol. 11, Chicago, IL, USA, June 4-8, 2010, pp. 336-340.
16. Eriksson B. New drugs in neuroendocrine tumors: rising of new therapeutic philosophies?. Curr. Opin. Oncol. 2010, 22:381-386.
17. Rinke A., Muller H.H., Schade-Brittinger C., Klose K.J., Barth P., Wied M., Mayer C., Aminossadati B., Pape U.F., Blaker M., Harder J., Arnold C., Gress T., Arnold R. PROMID study group, placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J. Clin. Oncol. 2009, 27:4656-4663.
18. Missiaglia E., Dalai I., Barbi S., Beghelli S., Falconi M., della Peruta M., Piemonti L., Capurso G., Di Florio A., delle Fave G., Pederzoli P., Croce C.M., Scarpa A. Pancreatic endocrine tumors: expression profiling evidences a role for Akt-mTOR pathway. J. Clin. Oncol. 2010, 28:245-255.
19. Jiao Y., Shi C., Edil B.H., de Wilde R.F., Klimstra D.S., Maitra A., Schulick R.D., Tang L.H., Wolfgang C.L., Choti M.A., Velculescu V.E., Diaz L.A., Vogelstein B., Kinzler K.W., Hruban R.H., Papadopoulos N. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011, 331:1199-1203.
20. Zhang J., Jia Z., Li Q., Wang L., Rashid A., Zhu Z., Evans D.B., Vauthey J.N., Xie K., Yao J.C. Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors. Cancer 2007, 109:1478-1486.
21. Food and Drug Administration, SUTENT® (sunitinib malate) prescribing information. <>. (accessed October 2012). http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021938s13s17s18lbl.pdf.
22. Food and Drug Administration, AFINITOR® (everolimus) prescribing information. <>. (accessed October 2012). http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022344s9s10lbl.pdf.
23. Catena L., Bajetta E., Milione M., Ducceschi M., Valente M., Dominoni F., Colonna V. Mammalian target of rapamycin expression in poorly differentiated endocrine carcinoma: clinical and therapeutic future challenges. Target Oncol. 2011, 6:65-68.
24. Shida T., Kishimoto T., Furuya M., Nikaido T., Koda K., Takano S., Kimura F., Shimizu H., Yoshidome H., Ohtsuka M., Tanizawa T., Nakatani Y., Miyazaki M. Expression of an activated mammalian target of rapamycin (mTOR) in gastroenteropancreatic neuroendocrine tumors. Cancer Chemother. Pharmacol. 2010, 65:889-893.
25. Grozinsky-Glasberg S., Franchi G., Teng M., Leontiou C.A., Ribeiro de Oliveira A., Dalino P., Salahuddin N., Korbonits M., Grossman A.B. Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell line. Neuroendocrinology 2008, 87:168-181.
26. Corbo V., Beghelli S., Bersani S., Antonello D., Talamini G., Brunelli M., Capelli P., Falconi M., Scarpa A. Pancreatic endocrine tumours: mutational and immunohistochemical survey of protein kinases reveals alterations in targetable kinases in cancer cell lines and rare primaries. Ann. Oncol. 2012, 23:127-134.
27. Inoki K., Li Y., Zhu T., Wu J., Guan K.L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 2002, 4:648-657.
28. Ghayouri M., Boulware D., Nasir A., Strosberg J., Kvols L., Coppola D. Activation of the serine/theronine protein kinase Akt in enteropancreatic neuroendocrine tumors. Anticancer Res. 2010, 30:5063-5067.
29. Corbo V., Dalai I., Scardoni M., Barbi S., Beghelli S., Bersani S., Albarello L., Doglioni C., Schott C., Capelli P., Chilosi M., Boninsegna L., Becker K.F., Falconi M., Scarpa A. MEN1 in pancreatic endocrine tumors: analysis of gene and protein status in 169 sporadic neoplasms reveals alterations in the vast majority of cases. Endocr. Relat. Cancer 2010, 17:771-783.
30. Wang Y., Ozawa A., Zaman S., Prasad N.B., Chandrasekharappa S.C., Agarwal S.K., Marx S.J. The tumor suppressor protein menin inhibits Akt activation by regulating its cellular localization. Cancer Res. 2011, 71:371-382.
31. Roldo C., Missiaglia E., Hagan J.P., Falconi M., Capelli P., Bersani S., Calin G.A., Volinia S., Liu C.G., Scarpa A., Croce C.M. MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J. Clin. Oncol. 2006, 24:4677-4684.
32. Kasajima A., Pavel M., Darb-Esfahani S., Noske A., Stenzinger A., Sasano H., Dietel M., Denkert C., Rocken C., Wiedenmann B., Weichert W. MTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours. Endocr. Relat. Cancer 2011, 18:181-192.
33. Perren A., Komminoth P., Saremaslani P., Matter C., Feurer S., Lees J.A., Heitz P.U., Eng C. Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. Am. J. Pathol. 2000, 157:1097-1103.
34. Sabatini D.M. MTOR and cancer: insights into a complex relationship. Nat. Rev. Cancer 2006, 6:729-734.
35. Smrz D., Kim M.S., Zhang S., Mock B.A., Smrzova S., DuBois W., Simakova O., Maric I., Wilson T.M., Metcalfe D.D., Gilfillan A.M. MTORC1 and mTORC2 differentially regulate homeostasis of neoplastic and non-neoplastic human mast cells. Blood 2011, 118:6803-6813.
36. O'Reilly K.E., Rojo F., She Q.B., Solit D., Mills G.B., Smith D., Lane H., Hofmann F., Hicklin D.J., Ludwig D.L., Baselga J., Rosen N. MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006, 66:1500-1508.
37. Liu P., Cheng H., Roberts T.M., Zhao J.J. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov. 2009, 8:627-644.
38. Knight Z.A., Gonzalez B., Feldman M.E., Zunder E.R., Goldenberg D.D., Williams O., Loewith R., Stokoe D., Balla A., Toth B., Balla T., Weiss W.A., Williams R.L., Shokat K.M. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 2006, 125:733-747.
39. Markman B., Dienstmann R., Tabernero J. Targeting the PI3K/Akt/mTOR pathway - beyond rapalogs. Oncotarget 2010, 1:530-543.
40. Engelman J.A., Luo J., Cantley L.C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 2006, 7:606-619.
41. Zitzmann K., De Toni E.N., Brand S., Goke B., Meinecke J., Spottl G., Meyer H.H., Auernhammer C.J. The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. Neuroendocrinology 2007, 85:54-60.
42. Moreno A., Akcakanat A., Munsell M.F., Soni A., Yao J.C., Meric-Bernstam F. Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocr. Relat. Cancer 2008, 15:257-266.
43. Yao J.C., Lombard-Bohas C., Baudin E., Kvols L.K., Rougier P., Ruszniewski P., Hoosen S., St Peter J., Haas T., Lebwohl D., Van Cutsem E., Kulke M.H., Hobday T.J., O'Dorisio T.M., Shah M.H., Cadiot G., Luppi G., Posey J.A., Wiedenmann B. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J. Clin. Oncol. 2010, 28:69-76.
44. Pavel M.E., Hainsworth J.D., Baudin E., Peeters M., Horsch D., Winkler R.E., Klimovsky J., Lebwohl D., Jehl V., Wolin E.M., Oberg K., Van Cutsem E., Yao J.C. RADIANT-2 Study Group, Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 2011, 378:2005-2012.
45. Yao J.C., Shah M.H., Ito T., Bohas C.L., Wolin E.M., Van Cutsem E., Hobday T.J., Okusaka T., Capdevila J., de Vries E.G., Tomassetti P., Pavel M.E., Hoosen S., Haas T., Lincy J., Lebwohl D., Oberg K. RAD001 in advanced neuroendocrine tumors, third trial (RADIANT-3) study group, everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med. 2011, 364:514-523.
46. Clinicaltrials.gov. . (accessed October 2012).
47. Gloesenkamp C., Nitzsche B., Lim A.R., Normant E., Vosburgh E., Schrader M., Ocker M., Scherubl H., Hopfner M. Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors. Int. J. Oncol. 2012, 40:1659-1667.
48. Beltran P.J., Mitchell P., Chung Y.A., Cajulis E., Lu J., Belmontes B., Ho J., Tsai M.M., Zhu M., Vonderfecht S., Baserga R., Kendall R., Radinsky R., Calzone F.J. AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells. Mol. Cancer Ther. 2009, 8:1095-1105.
49. Villaume K., Blanc M., Gouysse G., Walter T., Couderc C., Nejjari M., Vercherat C., Cordier-Bussat M., Roche C., Scoazec J.Y. VEGF secretion by neuroendocrine tumor cells is inhibited by octreotide and by inhibitors of the PI3K/Akt/mTOR pathway. Neuroendocrinology 2010, 91:268-278.
50. Gloesenkamp C.R., Nitzsche B., Ocker M., Di Fazio P., Quint K., Hoffmann B., Scherubl H., Hopfner M. Akt inhibition by triciribine alone or as combination therapy for growth control of gastroenteropancreatic neuroendocrine tumors. Int. J. Oncol. 2012, 40:876-888.
51. Zitzmann K., Vlotides G., Brand S., Lahm H., Spottl G., Goke B., Auernhammer C.J. Perifosine-mediated Akt inhibition in neuroendocrine tumor cells: role of specific Akt isoforms. Endocr. Relat. Cancer 2012, 19:423-434.
52. Hug H., Sarre T.F. Protein kinase C isoenzymes: divergence in signal transduction?. Biochem. J. 1993, 291:329-343.
53. Musashi M., Ota S., Shiroshita N. The role of protein kinase C isoforms in cell proliferation and apoptosis. Int. J. Hematol. 2000, 72:12-19.
54. Podar K., Tai Y.T., Davies F.E., Lentzsch S., Sattler M., Hideshima T., Lin B.K., Gupta D., Shima Y., Chauhan D., Mitsiades C., Raje N., Richardson P., Anderson K.C. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 2001, 98:428-435.
55. Mole D., Gagliano T., Gentilin E., Tagliati F., Pasquali C., Ambrosio M.R., Pansini G., Degli Uberti E.C., Zatelli M.C. Targeting protein kinase C by enzastaurin restrains proliferation and secretion in human pancreatic endocrine tumors. Endocr. Relat. Cancer 2011, 18:439-450.
56. Kulke M., Chan J.A., Ryan D.P., Meyerhardt J.A., Fuchs C.S., Abrams T.A., Regan E., Brady R., Weber J.M., Campos T., Kvols R., Strosberg J. A multi-institutional phase II open-label study of AMG-479 in advanced carcinoid and pancreatic neuroendocrine tumors. J. Clin. Oncol. 2012, 30(suppl). (Abstract 4125).
57. Hobday T.J., Qin R., Reidy D.L., Moore M.J., Strosberg J.R., Kaubisch A., Shah M.H., Kindler H.L., Lenz H., Chen H.X., Erlichman C. Multicenter phase II trial of temsirolimus (TEM) and bevacizumab (BEV) in pancreatic neuroendocrine tumor (PNET). J. Clin. Oncol. 2012, 30(suppl 4). (Abstract 260).
58. Hirai H., Sootome H., Nakatsuru Y., Miyama K., Taguchi S., Tsujioka K., Ueno Y., Hatch H., Majumder P.K., Pan B.S., Kotani H. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol. Cancer Ther. 2010, 9:1956-1967.
59. Yap T.A., Yan L., Patnaik A., Fearen I., Olmos D., Papadopoulos K., Baird R.D., Delgado L., Taylor A., Lupinacci L., Riisnaes R., Pope L.L., Heaton S.P., Thomas G., Garrett M.D., Sullivan D.M., de Bono J.S., Tolcher A.W. First-in-man clinical trial of the oral pan-Akt inhibitor MK-2206 in patients with advanced solid tumors. J. Clin. Oncol. 2011, 29:4688-4695.
60. Svejda B., Kidd M., Kazberouk A., Lawrence B., Pfragner R., Modlin I.M. Limitations in small intestinal neuroendocrine tumor therapy by mTOR kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and Akt. Cancer 2011, 117:4141-4154.
61. Hill R., Calvopina J.H., Kim C., Wang Y., Dawson D.W., Donahue T.R., Dry S., Wu H. PTEN loss accelerates KrasG12D-induced pancreatic cancer development. Cancer Res. 2010, 70:7114-7124.
62. Carracedo A., Pandolfi P.P. The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene 2008, 27:5527-5541.
63. Zitzmann K., Ruden J., Brand S., Goke B., Lichtl J., Spottl G., Auernhammer C.J. Compensatory activation of Akt in response to mTOR and RAF inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease. Cancer Lett. 2010, 295:100-109.
64. Meric-Bernstam F., Akcakanat A., Chen H., Do K.A., Sangai T., Adkins F., Gonzalez-Angulo A.M., Rashid A., Crosby K., Dong M., Phan A.T., Wolff R.A., Gupta S., Mills G.B., Yao J. PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Clin. Cancer Res. 2012, 18:1777-1789.
65. Chiu C.W., Nozawa H., Hanahan D. Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis. J. Clin. Oncol. 2010, 28:4425-4433.
66. Bergsland E.K. A phase II study to evaluate the safety and efficacy of RAD001 plus erlotinib in patients with well-differentiated neuroendocrine tumors (NET). Gastrointest. Cancers Sympos. 2012, (Abstract 285).
67. Shih K.C., Bendell J.C., Reinert A., Jones S., Kelley R.K., Infante J.R., Kom M., Hege K., Chopra R., Xu S., Wong L., Liu Y., Mortensen D., Munster P.N. Phase I trial of an oral TORC1/TORC2 inhibitor (CC-223) in advanced solid and hematologic cancers. J. Clin. Oncol. 2012, 30(suppl 4). (Abstract 3006).
68. Serra V., Markman B., Scaltriti M., Eichhorn P.J., Valero V., Guzman M., Botero M.L., Llonch E., Atzori F., Di Cosimo S., Maira M., Garcia-Echeverria C., Parra J.L., Arribas J., Baselga J. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res. 2008, 68:8022-8030.
69. Yao J.C., Phan A.T., Chang D.Z., Wolff R.A., Hess K., Gupta S., Jacobs C., Mares J.E., Landgraf A.N., Rashid A., Meric-Bernstam F. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J. Clin. Oncol. 2008, 26:4311-4318.
70. Serra S., Zheng L., Hassan M., Phan A.T., Woodhouse L.J., Yao J.C., Ezzat S., Asa S.L. The FGFR4-G388R single-nucleotide polymorphism alters pancreatic neuroendocrine tumor progression and response to mTOR inhibition therapy. Cancer Res. 2012, 72:5683-5691.